H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue

Immunitybio Inc. (NASDAQ:IBRX) is one of the fastest-growing penny stocks to buy now. On November 4, the company affirmed strong demand for Anktiva, used to treat bladder cancer, as it delivered impressive third-quarter results characterized by robust product sales. H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue The company delivered product revenue of $31.8 million, representing a 434% increase from the third quarter of last year. The year-ove ...